https://www.thebodypro.com/category/prezista-pro/tag/news

The Latest

three human skeleton models doing "see no evil, hear no evil, speak no evil"

This Week in HIV Research: Bone Concerns Aren’t Just for Older Folks

Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.

Updates for Prezista (Darunavir) for Use in Pregnant Women Img

Updates for Prezista (Darunavir) for Use in Pregnant Women

On June 17, 2016, the U.S. Food and Drug Administration approved updates to the Prezista (darunavir) labeling to include information on the use of darunavir in pregnant women.

Maintenance HIV Regimen of Rilpivirine and Boosted Darunavir as Effective as Three-Drug Treatment in Early Results Img

Maintenance HIV Regimen of Rilpivirine and Boosted Darunavir as Effective as Three-Drug Treatment in Early Results

Rilpivirine (Edurant) plus ritonavir-boosted darunavir (Prezista) as HIV maintenance therapy compared similarly to a three-drug regimen of a boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors, according to a study presente...

Pharmacokinetics in Pregnancy: Darunavir/Ritonavir and Etravirine Img

Pharmacokinetics in Pregnancy: Darunavir/Ritonavir and Etravirine

Two small studies presented at the 5th International Workshop on HIV & Women evaluated the pharmacokinetics of darunavir/ritonavir (DRV/r) and etravirine (ETV) respectively in pregnancy. In both studies drug exposure was altered -- lower for DRV and ...

Promo Image

Once-Daily Option for Pediatric Use of Prezista

On 1 February 2013, the FDA approved revisions to the darunavir (Prezista) tablet and oral suspension label to include paediatric use.

This included once daily dosing in treatment-naive subjects 3 to less than 18 years of age and once-daily dosing i...

Promo Image

Prezista (Darunavir) Label Change -- Drug Interaction Information

The FDA recently approved changes to the Prezista (darunavir) label to reflect drug interaction information with artemether/lumefantrine. The specific changes are outlined below.

Section 7: Drug Interactions

Antimalarials: artemether/lumefantrine -...

The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors Img

The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors

The FDA has approved an 800-mg tablet of darunavir for treatment naive patients. This single tablet will obviously replace the two darunavir 400-mg tablets in first-line therapy. (Yes, my math is that good.) Darunavir will still require 100-mg ritona...

Promo Image

Darunavir/Ritonavir and Etravirine as a Prevention Method Is Biologically Plausible

A pharmacokinetic study suggests that ritonavir-boosted darunavir (Prezista) and etravirine (Intelence) achieve high concentrations in semen and rectal tissue, and could therefore help avert HIV transmission and infection, especially in gay men. Conc...

Promo Image

FDA Approve Pediatric Dose for Darunavir

On December 16, 2011, The Food and Drug Administration approved an oral suspension formulation of darunavir (Prezista). Darunavir is now available as a 100 mg/mL oral suspension.

Additionally, the product labeling was updated to provide dosing recom...

Top 10 HIV/AIDS-Related Clinical Developments of 2011 Img

Top 10 HIV/AIDS-Related Clinical Developments of 2011

David Wohl, M.D., takes an in-depth look at this year's most critical HIV-related studies, and explains how each one may change how we prevent and treat HIV in 2012 and beyond. (Fair warning: This article can get pretty technical, but each story has ...